Back to search
A Protocol of Icotrokinra Therapy in Adult and Adolescent Participants With Moderately to Severely Active Ulcerative Colitis
Colitis, Ulcerative
Clinicaltrials.gov:
EU CTIS:
#2025-521381-10-00
Other:
#77242113UCO3001
Interested in this trial?
Email or download this trial
Trials at a glance
Status
Enrolling
Condition
Colitis, Ulcerative
Trial type
Interventional
Trial phase
Phase 3
Investigational
product
product
Icotrokinra
Placebo
Age
12+ years old
Biological sex
All
Placebo?
Yes
Trial start date
October 1, 2025
Trial end date
January 13, 2032
CT.gov ID
#NCT07196748
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Australia,
- Canada,
- Japan,
- Malaysia,
- Taiwan,
- United States
Loading...
Enrolling
Oakville, Ontario, Canada, L6L 5L7
Enrolling
Cutler Bay, Florida, United States, 33157
Enrolling
Kobe, Japan, 650-0015
Enrolling
Barrie, Ontario, Canada, L4M 7G1
Enrolling
Atlanta, Georgia, United States, 30342
Enrolling
Anaheim, California, United States, 92805
Enrolling
Topeka, Kansas, United States, 66606
Enrolling
Carrollton, Texas, United States, 75010
Enrolling
West Monroe, Louisiana, United States, 71291
Enrolling
Tampa, Florida, United States, 33609
Enrolling
Los Angeles, California, United States, 90067
Enrolling
Macon, Georgia, United States, 31201
Enrolling
Chūōku, Japan, 1040061
Enrolling
Kuala Lumpur, Malaysia, 50586
Enrolling
Johor Bahru, Malaysia, 80100
Enrolling
Alor Star, Malaysia, 05460
Enrolling
Kumamoto, Japan, 861-8520
Enrolling
Osaka, Japan, 543-0027
Enrolling
Kagoshima, Japan, 892-0843
Enrolling
Kumamoto, Japan, 860-8556
Enrolling
South Brisbane, Australia, 4101
Enrolling
Shizuoka, Japan, 432-8061
Enrolling
San Diego, California, United States, 92123
Enrolling
Okinawa, Japan, 904-2195
Enrolling
Kanazawa, Japan, 920-8650
Enrolling
Sunto-gun, Japan, 411-8611
Enrolling
Taipei, Taiwan, 100
Enrolling
Inverness, Florida, United States, 34452
Enrolling
New York, New York, United States, 10075
Enrolling
Ōita, Japan, 870-0033
Enrolling
Lancaster, California, United States, 93534
Enrolling
Oxnard, California, United States, 93030
Enrolling
Colorado Springs, Colorado, United States, 80907
Enrolling
Fujiidera-shi, Japan, 583-0027
Enrolling
Sapporo, Japan, 004-0041
Enrolling
San Antonio, Texas, United States, 78229
Enrolling
Kajang, Malaysia, 43000
Enrolling
Harrisburg, Pennsylvania, United States, 17110-3673
Enrolling
Los Angeles, California, United States, 90048
Enrolling
Miyagi, Japan, 981-3213
Enrolling
Portland, Oregon, United States, 97220-9428
Enrolling
Sumida Ku, Japan, 130 8575
Enrolling
Toronto, Ontario, Canada, M6A 3B4
Enrolling
Crestview Hills, Kentucky, United States, 41017
Enrolling
Kashiwa, Japan, 277-0871
Enrolling
Mississauga, Ontario, Canada, L5M 2S4
Enrolling
Carmel, New York, United States, 10512
Currently on Hold
Westlake, Ohio, United States, 44145
Currently on Hold
Chesapeake, Virginia, United States, 23320
Currently on Hold
Tyler, Texas, United States, 75701
Currently on Hold
Providence, Rhode Island, United States, 02905
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2025
